Bonk, Inc. (BNKK) Stock Jumps on Q3 2025 Earnings: Debt-Free Balance Sheet and 1,200% Beverage Revenue Surge

Bonk, Inc. (BNKK) Stock Jumps on Q3 2025 Earnings: Debt-Free Balance Sheet and 1,200% Beverage Revenue Surge

Bonk, Inc. (NASDAQ: BNKK) is back in the spotlight today after the company reported third-quarter 2025 results that complete its balance sheet cleanup, deliver triple‑digit revenue growth, and mark the first-ever gross profit for its beverage segment. Investors responded quickly:
Jacobs Solutions (J) Beats Q4 2025 Estimates, Targets 16% EPS Growth for 2026 on Record Backlog

Jacobs Solutions (J) Beats Q4 2025 Estimates, Targets 16% EPS Growth for 2026 on Record Backlog

Jacobs Solutions Inc. (NYSE: J) kicked off Thursday’s trading session with a flurry of news: stronger‑than‑expected fiscal fourth‑quarter 2025 results, a bullish 2026 earnings outlook, fresh SEC filings, and continued shareholder returns via dividends and buybacks. The engineering and professional
Freight Technologies (FRGT) Seals Fetch AI Deal and $1M Financing as Zayren Launch Supercharges Volatile Rally

Freight Technologies (FRGT) Seals Fetch AI Deal and $1M Financing as Zayren Launch Supercharges Volatile Rally

Freight Technologies, Inc. (NASDAQ: FRGT), the AI‑driven logistics platform known as Fr8Tech, is doubling down on its artificial intelligence strategy and reshaping its balance sheet after a dramatic stock surge. On Thursday, the company announced a multi‑year AI services agreement
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals Inc. (NASDAQ: INM) is back in the spotlight today after a sharp bounce in its share price, driven by fresh preclinical data for its Alzheimer’s disease candidate INM‑901 and heavy speculative trading in the micro‑cap biotech name. On
Go toTop